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Collagen secretion and growth of mesangial cells require gera- 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
nylgeranylpyrophosphate. reductase, which converts HMG-CoA to mevalonate, is
Background. The mevalonate pathway is important for the a rate-limiting enzyme of the mevalonate pathway. This
biosynthesis of isoprenoids such as geranylgeranylpyrophos-
pathway is important for the biosynthesis of isoprenoidsphate (GGPP) and farnesylpyrophosphate, as well as choles-
such as geranylgeranylpyrophosphate (GGPP) and far-terol. It has been reported that treatment with 3-hydroxy-3-
nesylpyrophosphate (FPP), as well as cholesterol [1]. Themethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor
ameliorates glomerular injury in several experimental models roles of the mevalonate pathway in cellular functions,
of progressive glomerular disease. However, the effect of HMG- particularly in the proliferation of mammalian cells, have
CoA reductase inhibitor on mesangial cell function has not been extensively investigated. It has been revealed thatbeen fully understood. This investigation was performed to
growth stimulation induces HMG-CoA reductase inelucidate the role of a mevalonate metabolite(s) in mesangial
many mammalian cells and that mevalonate and/or itscell proliferation and extracellular matrix accumulation.
Methods. Cycling or quiescent human mesangial cells were metabolite(s) plays a critical role in the proliferation of
incubated in RPMI 1640 containing 10% heat-inactivated fetal mammalian cells [2, 3]. It has also been demonstrated
calf serum (FCS) in the absence or presence of pravastatin, an that a number of small G proteins involved in the regula-
inhibitor of HMG-CoA reductase, and mevalonate metabolites. tion of intracellular signal transduction require modifi-Type IV collagen secretion, mRNA expression, and [3H]thymi-
cation by the metabolites of the mevalonate pathway,dine incorporation were measured. Cell cycle phases were mon-
GGPP and FPP, for their proper function [4, 5].itored by flow cytometry.
Results. Pravastatin inhibited FCS-stimulated type IV colla- Mesangial cell proliferation and accumulation of mes-
gen secretion (IC50 5 210 mm) and mRNA expression. Pravas- angial extracellular matrix are characteristic events in
tatin also inhibited FCS-stimulated [3H]thymidine incorpora- the process of many glomerular diseases. Therefore,
tion (IC50 5 430 mm). Analysis with flow cytometry revealed
drugs that lessen such events can be used for the inter-that pravastatin inhibited the G1 to S phase transition of FCS-
vention of glomerular diseases. HMG-CoA reductasestimulated mesangial cells. Mevalonate reversed these inhibi-
inhibitor is expected to be one of these drugs. It hastory effects of pravastatin completely. Among two major me-
tabolites of mevalonate, GGPP and farnesylpyrophosphate, been reported that treatment with HMG-CoA reductase
only GGPP reversed pravastatin-induced inhibition of type IV inhibitor ameliorates glomerular injury in several experi-
collagen secretion, DNA synthesis, and the G1 to S phase mental models of progressive glomerular disease [6–8].
progression.
Besides their ability to lower the lipid concentration inConclusions. These results suggest that GGPP plays critical
the circulation, simvastatin and lovastatin, inhibitors ofroles for the type IV collagen secretion and G1 to S phase
HMG-CoA reductase, have been shown to affect prolif-transition in FCS-stimulated human mesangial cells.
eration and apoptosis of mesangial cells. Simvastatin has
been shown to inhibit DNA synthesis in human mesan-
gial cells [9], and lovastatin has been shown to induceKey words: HMG-CoA, mevalonate, type IV collagen, cell cycle, iso-
prenoid, glomerular injury, geranylgeranylation. apoptosis of rat mesangial cells [10]. The results of these
reports suggest that the metabolite(s) of the mevalonateReceived for publication November 14, 1997
pathway plays an important role in mesangial cell prolif-and in revised form September 10, 1998
Accepted for publication September 10, 1998 eration and apoptosis. However, the effect of HMG-
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other than proliferation and apoptosis has not been fully following findings: (a) presence of spindle shaped mor-
phology; (b) ability to grow in medium containing D-understood. For example, little is known about the
involvement of the mevalonate cascade in the metabo- valine (unlike fibroblasts) and puromycin (unlike glo-
merular epithelial cells); (c) presence of immunochemi-lism of extracellular matrix. Furthermore, it is still un-
clear which metabolite(s) of the mevalonate pathway is cal staining for muscle actin and negative staining for
von Willebrand’s factor (unlike endothelial cells); andessential for the proliferation of human mesangial cells.
This investigation was performed to gain further in- (d) presence of angiotensin II receptor assessed by the
specific binding with 125I-angiotensin II. All experimentssight into the roles of the mevalonate cascade in mesan-
gial cell proliferation and extracellular matrix accumula- were performed using cells between passages 4 and 12.
tion. We examined whether the metabolites of the
Measurement of type IV collagen secretionmevalonate pathway play an essential role not only in
the proliferation of human mesangial cells, but also in Confluent human mesangial cells were used for the
experiment to study the effect of pravastatin on type IVthe accumulation of type IV collagen, one of the major
components of extracellular matrix, to determine which collagen secretion. These cells were referred to as cycling
mesangial cells. When cells reached confluence the cul-metabolite(s) of mevalonate is required for mesangial
cell proliferation and type IV collagen accumulation. ture media were changed. The cells were incubated for
another 48 hours in RPMI 1640 containing 10% heat-
inactivated FCS in the absence or presence of pravastatin
METHODS
(0 to 1,200 mm), mevalonate (0.5 mg/ml), liposomes con-
Reagents taining GGPP (2.5 to 10 mm) and FPP (10 mm). After 48
hours, the culture media were collected, and type IVRPMI 1640 medium and fetal calf serum (FCS) were
purchased from Gibco BRL (Rockville, MD, USA). collagen secreted into culture media was measured by
enzyme immunoassay using Panassay IV C (Daiichi Pure[3H]thymidine was purchased from Amersham Interna-
tional, (Buckinghamshire, UK). Pravastatin, an inhibitor Chemical Co., Tokyo, Japan). Data are expressed as the
percentage of positive control (type IV collagen secre-of HMG-CoA reductase, was kindly provided from San-
kyo Pharmaceutical Co. (Tokyo, Japan). tion from cells incubated in 10% FCS).
RNA isolation and Northern blot analysisPreparation of liposomes of isoprenoids
[3H]Geranylgeranylpyrophosphate and [3H]farnesyl- When cells reached confluence, culture media were
changed to RPMI 1640 containing 10% heat-inactivatedpyrophosphate were purchased from DuPont NEN
(Boston, MA, USA). GGPP and FPP were purchased FCS and pravastatin (1,200 mm). Total RNA from the
cells at various times (0 to 72 hr) after the initiation offrom Sigma Chemical Co. (St. Louis, MO, USA). To
make liposomes containing each, an aliquot of a mixture pravastatin treatment was isolated as described pre-
viously [12]. To study the effect of mevalonate on theof dipalmitoylphosphatidylcholine (5 mmol) and GGPP
(200 mg) or FPP (200 mg) was added to a pear-shaped inhibitory effect of pravastatin, mevalonate (0.5 mg/ml)
was added into the culture medium when the pravastatinflask, and the solvent was removed by rotary evapora-
tion. The dried lipid film was then dispersed in 0.5 ml treatment was initiated. RNA samples (10 mg) were elec-
trophoretically separated on a 1.1% formaldehyde aga-of phosphate-buffered saline (PBS). Warming the flask
to 508C facilitated smooth dispersion. The liposomes rose gel, blot-transferred onto nitrocellulose paper, and
then hybridized with 32P-labeled type IV collagen andwere sonicated and stored at 48C [11].
b-actin probes. The type IV collagen cDNA probe was
Cell culture and characterization kindly provided by Dr. S. Kaname (Tokyo University,
Tokyo, Japan) [13].Human kidneys were obtained from patients undergo-
ing nephrectomy for renal cell carcinoma. Normal kidney
Western blot analysistissue surrounding the tumor was dissected. The cortex
was separated from the medulla, finely minced, and The effect of pravastatin on the actin content in muscle
was examined by Western blot analysis. When cellspassed through a 150 mm metal sieve, and the material
underside was collected. The suspension was passed reached confluence, they were incubated for another 48
hours in RPMI 1640 containing 10% heat-inactivatedthrough a 75 mm metal sieve, which retained the glomer-
ular cores. Mesangial cells were grown from the collagen- FCS in the absence or presence of pravastatin (1,200
mm). Cells were also incubated in RPMI 1640 containingase-digested glomeruli. The cells were cultured in RPMI
1640 supplemented with 10% heat-inactivated FCS, 10 0.5% bovine serum albumin (BSA). After 48 hours, cells
were collected, and whole cell lysates were prepared asmg/ml insulin, 10 mg/ml transferrin, 10 ng/ml selenium
(Sigma), 50 U/ml penicillin, and 100 mg/ml streptomycin. described before [10]. Briefly, the collected cells were
resuspended in a cold lysis buffer (50 mm HEPES, pHCells were identified as mesangial cells according to the
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7.0, 2 mm MgCl2, 250 mm NaCl, 0.1 mm ethylenediamine- with propidium iodide using the CycleTEST PLUS DNA
reagent kit (Becton Dickinson Immunocytometry Sys-tetraacetic acid, 0.1 mm EGTA, 1 mm DTT, 2 mm
Na2VO4, 10 mm Na4P2O7, 10 mm NaF, 0.1% NP-40, 0.5 tems, San Jose, CA, USA) according to the manufactur-
er’s instructions. The cell cycle profiles of samples weremm p-amidinophenyl methanesulfonyl fluoride hydro-
chloride with a protease inhibitor cocktail (2.5 mg/ml of analyzed by FACScan (Becton Dickinson).
pepstatin A, 2.5 mg/ml of antipain, 2.5 mg/ml of chymo-
Statistical analysisstatin, 0.25 mg/ml of leupeptin, and 0.25 mg/ml of anti-
pain). The cells were allowed to lyze on ice for 60 min- All data are presented as means 6 sd. Analysis of
variance was performed in evaluation of the data. Putes. Then the homogenate was centrifuged for five
minutes in a microfuge at 48C, and the supernatant was values less than 0.05 were considered significant in all
cases.examined by Western blot analysis. Protein concentra-
tion was determined using a Bio-Rad Kit (Bio-Rad Lab
Inc., Hercules, CA, USA). Twenty micrograms of pro-
RESULTS
teins were run on a 12% denaturing polyacrylamide gel
Effect of pravastatin and mevalonate metabolites onand blotted on a nitrocellulose membrane (Bio-Rad)
type IV collagen secretion and gene expression inusing a semidry transfer system (Bio-Rad). The mem-
human mesangial cells stimulated by 10% FCSbrane was blocked at 48C for 12 hours in PBS plus 0.1%
Tween 20 plus 1% BSA. Rabbit polyclonal antihuman Pravastatin caused a dose-dependent suppression in
FCS-stimulated type IV collagen secretion from mesan-muscle actin antibody was used as the primary antibody
(Biomedical Technologies Inc., Stoughton, MA, USA). gial cells (IC50 5 210 mm), and pravastatin inhibited
48.4% of FCS-stimulated type IV collagen secretion atThe enhanced chemiluminescence system (Amersham)
was used for the luminescence detection of horseradish 1,200 mm (Fig. 1). This inhibition was fully recovered by
the addition of mevalonate (0.5 mg/ml), indicating thatperoxidase-conjugated second antibody.
the observed inhibition of type IV collagen secretion was
Measurement of DNA synthesis due to the decrease of mevalonate production occurring
because of HMG-CoA reductase inhibition. MevalonateDNA synthesis was measured as the incorporation of
[3H]thymidine into trichloroacetic acid-insoluble mate- is a donor for the synthesis of several important metabo-
lites involved in the post-translational modification ofrial. Subconfluent human mesangial cells in 24-well
dishes were made quiescent by placing them in serum- proteins. It acts as an isoprenyl precursor for farnesyl
and geranylgeranyl molecules, which have an importantfree RPMI 1640 medium containing 0.5% BSA, 50
U/ml penicillin, and 100 mg/ml streptomycin for 48 signaling function. These data suggest that mevalonate
itself and/or some of its metabolites are required for typehours. These cells were referred to as quiescent mesan-
gial cells. Then the cells were stimulated by RPMI 1640 IV collagen secretion from the FCS-stimulated human
mesangial cells. Therefore, we examined the effect ofcontaining 10% FCS for 24 hours. Pravastatin (100 to
1,200 mm), mevalonate (0.5 mg/ml), liposomes containing GGPP and FPP on the inhibitory effect of pravastatin.
As shown in Figure 2, the inhibitory effect of pravastatinGGPP (2.5 to 10 mm) and FPP (10 mm) were added
into culture media when serum stimulation was initiated. (1,200 mm) on type IV collagen secretion was reversed
dose dependently by the addition of liposomes con-During the last four hours of the incubation period, the
cells were pulsed with [3H]thymidine (1 mCi/well). The taining GGPP, and was fully recovered at 5 mm. On the
other hand, liposomes containing FPP had little effect.media were removed, and the cells were washed with
ice-cold PBS three times. Acid-insoluble materials were The effect of pravastatin (1,200 mm) on type IV collagen
mRNA expression in human mesangial cells was alsoprecipitated with ice-cold 5% trichloroacetic acid. Then
cells were solubilized with 500 ml of 0.5 n KOH. Aliquots examined. As shown in Figure 3, treatment of human
mesangial cells with pravastatin (1,200 mm) reduced typewere then counted in the scintillation fluid. In the experi-
ments to examine the time course of the effect of GGPP, IV collagen mRNA expression time dependently, and a
maximum inhibition was observed 24 hours after pravas-GGPP was added at various times (0 to 12 hours) after
the pravastatin treatment was initiated. Data are ex- tatin treatment. This inhibition was also reversed by mev-
alonate (0.5 mg/ml). On the other hand, expression ofpressed as the percentage of positive control ([3H]thymi-
dine incorporation into 10% FCS-stimulated cells). actin mRNA was not affected by pravastatin (1,200 mm).
The effect of pravastatin on muscle actin synthesis was
Flow cytometric analysis also examined by Western blot analysis to determine
whether the inhibitory effect of pravastatin on type IVCell cycle phases were monitored by flow cytometry.
Briefly, 10% FCS-stimulated human mesangial cells collagen secretion is specific or nonspecific. As shown in
Figure 4, pravastatin (1,200 mm) had no effect on thewere collected 20 hours after incubation and were
washed with PBS. Human mesangial cells were stained muscle actin content in human mesangial cells.
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Fig. 1. Effect of pravastatin on type IV colla-
gen secretion from human mesangial cells
stimulated by fetal calf serum (FCS). Cycling
human mesangial cells were incubated with
10% FCS in the presence or absence of various
concentrations of pravastatin (100 to 1,200
mm) for 48 hours. Type IV collagen secreted
into culture media was measured, and data
are expressed as the percentage of positive
control (type IV collagen secretion from 10%
FCS-stimulated cells). Data represent the
mean 6 sd of three separate experiments each
done in triplicate (**P , 0.01).
Fig. 2. Effect of pravastatin and mevalonate
metabolites on type IV collagen secretion from
human mesangial cells stimulated by FCS. Cy-
cling human mesangial cells were incubated
with 10% FCS in the presence or absence of
pravastatin (1,200 mm) and liposomes contain-
ing geranylgeranylpyrophosphate or farnesyl-
pyrophosphate for 48 hours. Type IV collagen
secreted into culture media was measured, and
data are expressed as the percentage of posi-
tive control (type IV collagen secretion from
10% FCS-stimulated cells). Data represent
the mean 6 sd of four separate experiments
each done in triplicate (**P , 0.01).
Effect of pravastatin on DNA synthesis and cell cycle pressed the increased S-phase population stimulated by
progression in human mesangial cells stimulated by 10% FCS from 20.7% (10% FCS) to 3.4% (10% FCS
10% FCS plus 1,200 mm pravastatin), indicating that pravastatin
inhibited G1 to S phase transition in 10% FCS-stimu-Pravastatin caused a dose-dependent suppression in
lated human mesangial cells. This inhibitory effect ofFCS-stimulated DNA synthesis in the mesangial cell
pravastatin on G1 to S phase progression was also re-(IC50 5 430 mm) (Fig. 5). This inhibition was recovered
versed by mevalonate (0.5 mg/ml; data not shown).by the addition of mevalonate dose dependently and was
The effect of GGPP and FPP on pravastatin-inducedfully recovered at 0.5 mg/ml. The inhibition of HMG-
inhibition of FCS-stimulated DNA synthesis was alsoCoA reductase on cell cycle progression was further
characterized by flow cytometry (Fig. 6). Pravastatin sup- examined. As shown in Figure 7, [3H]thymidine incorpo-
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Fig. 3. Effect of pravastatin and mevalonate
on type IV collagen and actin mRNA in hu-
man mesangial cells stimulated by FCS. Cy-
cling human mesangial cells were incubated
with 10% FCS and pravastatin (1,200 mm) for
various times (0 to 72 hr). In one incubation,
mevalonate (0.5 mg/ml) was also added to the
culture medium. Total RNA was extracted
from the cells, and Northern blot analysis was
performed. (A) Total RNA was extracted be-
fore pravastatin treatment was initiated (0 hr).
(B–E) Total RNA was extracted at (B) 12
hours, (C) 24 hours, (D) 48 hours, and (E) 72
hours after pravastatin treatment was initi-
ated. (F) Total RNA was extracted 48 hours
after pravastatin and mevalonate treatment
was initiated.
Fig. 4. Effect of pravastatin on actin content
in human mesangial cells stimulated by FCS.
Cycling human mesangial cells were incubated
for another 48 hours with (A) 0.5% BSA, (B)
10% FCS, (C) 10% FCS in the presence of
pravastatin (1,200 mm). Whole cell lysate of
human mesangial cells was prepared, and
Western blot analysis was performed.
Fig. 5. Effect of pravastatin and mevalonate
on DNA synthesis in human mesangial cells
stimulated by FCS. Quiescent human mesan-
gial cells were incubated with 10% FCS in the
presence or absence of various concentrations
of pravastatin or mevalonate for 24 hours.
[3H]Thymidine incorporation was measured,
and data are expressed as the percentage of
positive control ([3H]thymidine incorporation
into 10% FCS-stimulated cells). Data repre-
sent the mean 6 sd of three to four separate
experiments each done in duplicate (**P ,
0.01).
Nishimura et al: Mesangial cell and geranylgeranylpyrophosphate 525
Fig. 6. Effect of pravastatin and mevalonate metabolites on cell cycle progression determined by flow cytometry in human mesangial cells.
Quiescent human mesangial cells were incubated with (A) 0.5% BSA, (B) 10% FCS, (C) 10% FCS in the presence of pravastatin (1,200 mm), (D)
10% FCS in the presence of pravastatin (1,200 mm) and liposomes containing no isoprenoids, (E) 10% FCS in the presence of pravastatin (1,200
mm) and geranylgeranylpyrophosphate (10 mm) in liposomes, (F) 10% FCS in the presence of pravastatin (1,200 mm) with farnesylpyrophosphate
(10 mm) in liposomes for 20 hours. Cells were stained with propidium iodide and analyzed by FACSan.
ration into pravastatin (1,200 mm)-treated cells was in Figure 6, the addition of GGPP (10 mm) reversed
23.1% of the positive control ([3H]thymidine incorpora- the pravastatin-induced inhibition of the G1 to S phase
tion into 10% FCS-stimulated human mesangial cells). transition. On the other hand, the addition of FPP (10
Liposomes containing GGPP dose dependently reversed mm) only partly reversed the pravastatin-induced in-
the inhibitory effect of pravastatin (1,200 mm) on DNA hibition of G1 to S phase transition.
synthesis, and a maximal effect was observed at 10 mm
(data not shown). At this concentration, [3H]thymidine
DISCUSSIONincorporation recovered to 72.0% of the positive control.
In this study, we have first demonstrated that treat-On the other hand, liposomes containing FPP (10 mm)
ment of FCS-stimulated human mesangial cells with pra-had less effect, and [3H]thymidine incorporation was only
vastatin, an inhibitor of HMG-CoA reductase, reduced35.6% of the positive control, although incorporation
type IV collagen gene expression and secretion. We alsoof [3H]farnesylpyrophosphate in liposomes into human
have demonstrated that pravastatin inhibits FCS-inducedmesangial cells was almost equal to that of [3H]geranyl-
DNA synthesis in human glomerular mesangial cells atgeranylpyrophosphate (data not shown). Liposomes con-
the G1 to S phase transition of cell cycle progression.taining no isoprenoids (vehicle alone) had no effect on
These inhibitory effects of pravastatin on functions ofthe inhibitory effect of pravastatin on 10% FCS-stimu-
human mesangial cells were completely reversed by mev-lated DNA synthesis. GGPP exerted its effect to restore
alonate, which suggests that mevalonate or its metabo-the pravastatin-induced inhibition fully only when it was
lites play important roles in the regulation of these func-added within two hours in pravastatin-treated cells (Fig.
tions of human mesangial cells. Although the roles of8). The role of mevalonate metabolites in cell cycle pro-
gression was also examined by flow cytometry. As shown the mevalonate cascade in cell proliferation have been
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converted to GGPP. This means that GGPP can rescue
the pravastatin-induced inhibition of type IV collagen se-
cretion and the G1 to S phase transition without upstream
intermediates of cholesterol biosynthesis (Fig. 9).
It has been demonstrated that many proteins are modi-
fied by isoprenoids. This modification is necessary for
proper cellular localization and function of the proteins
[4, 5]. A number of small G-proteins such as Ras, Rho
and Rac have been shown to be involved in the G1 to
S phase transition of the cell cycle progression. As these
proteins require prenylation for their proper function,
it is suggested that the inhibitory effect of HMG-CoA
Fig. 7. Effect of pravastatin and mevalonate metabolites on DNA syn-
reductase inhibitor on cell proliferation is attributed tothesis of human mesangial cells stimulated by FCS. Quiescent human
mesangial cells were incubated with (A) 0.5% BSA, (B) 10% FCS, (C) an inhibition of prenylation in these small G-proteins
10% FCS in the presence of pravastatin (1,200 mm), (D) 10% FCS in [14, 15]. It is generally accepted that Ras proteins play
the presence of pravastatin (1,200 mm) and liposomes containing no
a pivotal role in cell proliferation and require farnesyla-isoprenoids, (E) 10% FCS in the presence of pravastatin (1,200 mm)
and geranylgeranylpyrophosphate (10 mm) in liposomes, (F) 10% FCS tion for their biological activity. The inhibition of Ras
in the presence of pravastatin (1,200 mm) with farnesylpyrophosphate farnesylation leads to inhibition of cell proliferation [16,
(10 mm) in liposomes for 24 hours. [3H]Thymidine incorporation was
17]. However, recent studies demonstrated the impor-measured, and data are expressed as the percentage of positive control
([3H]thymidine incorporation into 10% FCS-stimulated cells). Data rep- tance of protein geranylgeranylation, not farnesylation,
resent mean 6 sd of five separate experiments each done in duplicate in cell proliferation. Vogt et al reported that protein ger-
(**P , 0.01).
anylgeranylation is required in cell cycle progression of
mouse fibroblasts [18]. Hirai et al and Noguchi et al re-
ported that geranylgeranylation of Rho small GTPase(s)
is essential for the cell cycle progression in rat thyroidinvestigated in various mammalian cells, this is the first
report, to our knowledge, demonstrating that the meval- FRTL-5 cells [11, 19].
In rat mesangial cells, Ghosh et al reported that lova-onate cascade is also involved in the regulation of secre-
tion of the extracellular matrix. statin induces apoptosis [10]. They also demonstrated
that Rho A accumulated in the cytosol in lovastatin-Mevalonate acts as an isoprenyl precursor for farnesyl
or geranylgeranyl molecules, as well as a precursor for treated mesangial cells, which suggests that Rho A must
be prenylated for its activation. KB Ras, Rac, and Rhocholesterol (Fig. 9). It has been reported that cholesterol
does not reverse the inhibitory effect of HMG-CoA re- A are substrates for geranylgeranyltransferase, and are
thought to play major roles in cell cycle progression [15].ductase inhibitor on DNA synthesis in human mesangial
cells [9]. Therefore, exogenous FPP and/or GGPP might Therefore, they can be good candidates for the geranyl-
geranylated protein(s) that is important for cell cycle pro-be expected to counteract the effect of pravastatin. Un-
fortunately, the experimental use of these compounds is gression. On the other hand, the precise mechanisms by
which the mevalonate cascade influences the metabolismlimited by their membrane impermeability and sensitiv-
ity to thiol reagents present in the culture medium. of the extracellular matrix are not yet fully understood.
As shown in Figure 1, collagen secretion was suppressedTherefore, we prepared the liposomes containing these
compounds to examine which of the mevalonate metabo- in FCS-deprived mesangial cells. Two possibilities could
explain this result: (a) cell cycle progression is requiredlites is important for the regulation of the cell cycle
progression in human mesangial cells. As shown in Fig- before collagen secretion; and (b) deprivation of some
factor(s) contained in FCS or produced by FCS-stimu-ures 2, 6, and 7, the inhibitory effects of pravastatin on
type IV collagen secretion, DNA synthesis, and the G1 lated mesangial cells is responsible for suppressed colla-
gen secretion. Therefore, pravastatin-inhibited type IVto S phase transition were reversed by the liposomes
containing GGPP, but not by those containing FPP. collagen secretion could be attributed to the inhibition
of cell cycle progression and/or the inhibition of theGhosh et al showed that the addition of farnesol or
geranylgeraniol to lovastatin-treated cells caused cell cy- effect of some factors to stimulate collagen synthesis.
The precise mechanism of pravastatin to inhibit type IVcle progression [10]. This result is different from that of
ours. In our experiment, FPP had very little effect on collagen secretion needs to be elucidated in future.
In conclusion, these results demonstrate that in humanpravastatin-treated mesangial cells to cause cell cycle
progression. GGPP is biosynthetically derived from the mesangial cells, the intrinsic mevalonate cascade plays
a critical role in type IV collagen gene expression, secre-single condensation of FPP and isopentenylpyrophos-
phate. Because isopentenylpyrophosphate could not be tion, and the transition from the G1 to S phase of cell
growth, and that among mevalonate metabolites, GGPPsynthesized in pravastatin-treated cells, FPP could not be
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Fig. 8. Time course of the effect of GGPP to
restore pravastatin-inhibited DNA synthesis of
FCS-stimulated human mesangial cells. Qui-
escent human mesangial cells were incubated
with 10% FCS in the presence of pravastatin
(1,200 mm) for 24 hours. GGPP was added
to culture media at various times after 10%
FCS and pravastatin treatment was initiated.
[3H]Thymidine incorporation was measured,
and data are expressed as the percentage of
positive control ([3H]thymidine incorporation
into 10% FCS-stimulated cells). Data represent
mean 6 sd (N 5 4; *P , 0.05, **P , 0.01).
Fig. 9. Biochemical steps of the mevalonate
pathway. HMG-CoA is 3-hydroxy-3-methyl-
glutaryl-coenzyme A; * is condensation.
and M. Nangaku for the type IV collagen cDNA probe; and E. Hata-is essential for these functions to occur. It would be
keyama, Y. Tsuchikawa, K. Okuda, and M. Maemori for their excellent
important to determine which protein(s) is geranylgera- technical assistance.
nylated and essential for these functions of human mes-
Reprint requests to: Dr. Motonobu Nishimura, Department of Inter-angial cells. Recently, the enzymes that catalyze the cova-
nal Medicine, Sakura National Hospital, 2-36-2, Ebaradai, Sakura-city,
lent attachment of geranylgeranyl moieties to proteins Chiba, 285 Japan.
E-mail:mnishi@hosp.Sakura-nh.go.jpare well characterized [20], and inhibitors of geranylgera-
nyltransferase are synthesized [21]. The use of these
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